Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106353 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT00106353 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 71 participants.
The verdict
NCT00106353, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
This is an open label, two-part study of temsirolimus given as a 60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity. (recruiting)
Interventions
- DRUG Torisel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2005-03 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00106353
The ClinicalTrials.gov registry entry for NCT00106353 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Torisel is the first listed.
NCT00106353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00106353 about?
NCT00106353 is a clinical study titled "Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors". This is an open label, two-part study of temsirolimus given as a 60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanc...
What is the current status of trial NCT00106353?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2005-03. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00106353?
The interventions under investigation include: Torisel (DRUG).
Who is sponsoring clinical trial NCT00106353?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.